Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: JNJ MRK PFE ABBV BMY LLY GSK NVS SAN AZN-D

| Held by: IJR VTI VB PEY VBR VXF SMIG IJS SPSM SDY

Index	-	P/E	-	EPS (ttm)	-0.38	Insider Own	0.49%	Shs Outstand	137.60M	Perf Week	-0.68%
Market Cap	2.00B	Forward P/E	5.44	EPS next Y	2.67	Insider Trans	2.84%	Shs Float	136.95M	Perf Month	-2.15%
Enterprise Value	5.40B	PEG	1.97	EPS next Q	0.79	Inst Own	108.51%	Short Float	11.57%	Perf Quarter	2.68%
Income	-51.80M	P/S	0.47	EPS this Y	8.16%	Inst Trans	2.12%	Short Ratio	4.69	Perf Half Y	-36.86%
Sales	4.28B	P/B	0.45	EPS next Y	-3.91%	ROA	-0.27%	Short Interest	15.85M	Perf YTD	4.45%
Book/sh	32.31	P/C	4.63	EPS next 5Y	2.77%	ROE	-0.65%	52W High	30.93 -52.99%	Perf Year	-41.37%
Cash/sh	3.14	P/FCF	7.37	EPS past 3/5Y	-12.80% -	ROIC	-0.63%	52W Low	12.17 19.47%	Perf 3Y	-59.23%
Dividend Est.	1.16 (7.98%)	EV/EBITDA	7.56	Sales past 3/5Y	1.84% -1.99%	Gross Margin	35.43%	Volatility	2.82% 3.60%	Perf 5Y	-67.67%
Dividend TTM	1.16 (7.98%)	EV/Sales	1.26	EPS Y/Y TTM	66.00%	Oper. Margin	8.89%	ATR (14)	0.49	Perf 10Y	-89.51%
Dividend Ex-Date	Nov 28, 2025	Quick Ratio	1.44	Sales Y/Y TTM	-2.55%	Profit Margin	-1.21%	RSI (14)	51.75	Recom	2.00
Dividend Gr. 3/5Y	4.64% 6.05%	Current Ratio	2.51	EPS Q/Q	142.19%	SMA20	0.47%	Beta	0.39	Target Price	18.67
Payout	-	Debt/Eq	0.86	Sales Q/Q	-4.14%	SMA50	2.94%	Rel Volume	0.41	Prev Close	14.38
Employees	8379	LT Debt/Eq	0.85	Earnings	Feb 26 BMO	SMA200	-30.47%	Avg Volume	3.38M	Price	14.54
IPO	Dec 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.09% -4.80%	Trades		Volume	1,393,031	Change	1.11%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-25	Downgrade	JP Morgan	Overweight → Neutral	$20
Jan-14-25	Downgrade	Argus	Buy → Hold
Jan-06-25	Downgrade	Piper Sandler	Overweight → Neutral	$34 → $27
Sep-24-24	Resumed	Jefferies	Hold	$50 → $30
Nov-17-23	Initiated	Piper Sandler	Overweight	$37
Mar-07-23	Initiated	Canaccord Genuity	Buy	$49
Sep-14-22	Upgrade	Argus	Hold → Buy	$46
Sep-06-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$48 → $54
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform	$59
Sep-30-21	Upgrade	Jefferies	Hold → Buy	$45 → $63
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform	$51
Jan-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$59 → $49
Apr-17-20	Downgrade	Argus	Buy → Hold
Mar-24-20	Upgrade	JP Morgan	Neutral → Overweight	$57
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$54 → $52
Mar-18-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$58
Oct-11-19	Upgrade	Argus	Hold → Buy
Mar-20-19	Initiated	SunTrust	Hold
Nov-13-18	Downgrade	Berenberg	Buy → Hold
Aug-10-18	Reiterated	Stifel	Hold	$92 → $87

Show Previous Ratings

Feb-13-26 08:30AM	Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 (PR Newswire)
Feb-06-26 08:25AM	Canopy Growth Corporation (CGC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Jan-23-26 06:04AM	PEYs 50 Stocks Create 4.95% Income But Three Major Holdings Are Waving Red Flags (24/7 Wall St.)
Jan-14-26 03:37AM	Perrigo Company plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRGO (PR Newswire)
Jan-05-26 02:21PM	Analyst Report: Perrigo Company plc (Morningstar Research)
09:00AM	Loading…
Jan-02-26 09:00AM	Perrigo Company plc Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - PRGO (PR Newswire)
Dec-29-25 02:41AM	Perrigo Company plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRGO (PR Newswire)
Dec-23-25 05:50PM	Perrigo (PRGO) Target Reduced as JPMorgan Refreshes Estimates (Insider Monkey)
Dec-19-25 02:56PM	Did You Lose Money in Perrigo Company? PRGO Stockholders Should Contact Robbins LLP for Information About Their Rights Against PRGO. (Business Wire)
Dec-11-25 07:47AM	Perrigo Company plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRGO (PR Newswire)
Dec-08-25 03:00AM	Perrigo Company plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRGO (PR Newswire)
Dec-05-25 05:49PM	CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
11:30AM	Perrigo (PRGO) Down 9.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-02-25 09:00AM	Perrigo Company plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - PRGO (PR Newswire)
Dec-01-25 08:35AM	Should You Hold Your Stake in Perrigo Company, plc (PRGO)? (Insider Monkey)
03:50AM	Loading…
03:50AM	Perrigo Company plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRGO (PR Newswire)
Nov-26-25 07:50AM	Perrigo Company plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights PRGO (Business Wire)
Nov-18-25 08:00AM	Perrigo to Attend Morgan Stanley Global Consumer & Retail Conference (PR Newswire)
Nov-17-25 01:40PM	Canaccord Maintains Buy on Perrigo (PRGO) While Cutting Price Target to $20 (Insider Monkey)
Nov-06-25 12:07PM	Perrigo (PRGO) Falls to 52-Week Low on Weak Sales, Infant Formula Review (Insider Monkey)
Nov-05-25 04:23PM	Analyst Report: Perrigo Company plc (Morningstar Research) -25.21%
04:04PM	Perrigo Co PLC (PRGO) Q3 2025 Earnings Call Highlights: Strategic Gains Amid Market Challenges (GuruFocus.com)
02:18PM	Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Perrigo (PRGO) Q3 Earnings (Zacks)
07:45AM	Perrigo (PRGO) Q3 Earnings Surpass Estimates (Zacks)
06:46AM	Perrigo: Q3 Earnings Snapshot (Associated Press Finance)
06:35AM	Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations (PR Newswire)
06:30AM	Perrigo to Conduct Strategic Review of its Infant Formula Business (PR Newswire)
Nov-04-25 08:45AM	Perrigo to Attend Jefferies Consumer Conference (PR Newswire)
Oct-30-25 10:00AM	Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
11:57AM	Loading…
Oct-29-25 11:57AM	Perrigo Announces Quarterly Dividend (PR Newswire)
10:00AM	Earnings Preview: Perrigo (PRGO) Q3 Earnings Expected to Decline (Zacks)
Oct-22-25 08:30AM	Perrigo to Release Third Quarter 2025 Financial Results on November 5, 2025 (PR Newswire)
Oct-13-25 11:01PM	Solid Dividend Yield and 22 Years of Growth Highlight Perrigo's (PRGO) Investor Appeal (Insider Monkey)
Oct-09-25 08:00AM	Opill Nails It with First-Ever Brand Collaboration, Launching 'Opill and Chill' With Chillhouse (PR Newswire)
Sep-18-25 10:45AM	Perrigo Company plc (PRGO) Reports $1.06B Q2 Sales, Advances 'Three-S' Strategy (Insider Monkey)
Sep-16-25 09:29AM	Perrigo Company plc (PRGO) Sells Dermacosmetics Unit in 327M Deal (Insider Monkey)
Aug-20-25 07:30AM	Perrigo to Attend Barclays 18th Annual Global Consumer Staples Conference (PR Newswire)
Aug-11-25 09:40AM	Are Investors Undervaluing Perrigo (PRGO) Right Now? (Zacks)
09:15AM	International Markets and Perrigo (PRGO): A Deep Dive for Investors (Zacks)
Aug-08-25 09:35AM	Perrigo (PRGO) Loses 16.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-07-25 07:23PM	Analyst Report: Perrigo Company plc (Morningstar Research)
Aug-06-25 03:27PM	Analyst Report: Perrigo Company plc (Morningstar Research) -11.31%
02:14PM	Emerson Electric slips, Carmax upgraded, Perrigo sales miss (Yahoo Finance Video)
11:07AM	Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut (Zacks)
09:30AM	Perrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
07:45AM	Perrigo (PRGO) Lags Q2 Earnings and Revenue Estimates (Zacks)
06:41AM	Perrigo: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations (PR Newswire)
Aug-05-25 09:55AM	Wall Street Analysts Think Perrigo (PRGO) Could Surge 36.02%: Read This Before Placing a Bet (Zacks)
Aug-01-25 07:57AM	Perrigo (PRGO) Expects Enhanced Profitability and Earnings Growth from Strategic Execution (Insider Monkey)
Jul-30-25 12:55PM	Perrigo Announces Quarterly Dividend (PR Newswire)
11:07AM	Perrigo to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Jul-29-25 08:30AM	Perrigo to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
Jul-25-25 09:40AM	Is Perrigo (PRGO) Stock Undervalued Right Now? (Zacks)
Jul-23-25 08:30AM	Perrigo to Release Second Quarter 2025 Financial Results on August 6, 2025 (PR Newswire)
Jul-21-25 12:33PM	Analyst Report: Perrigo Company plc (Morningstar Research)
Jul-17-25 09:55AM	Wall Street Analysts Believe Perrigo (PRGO) Could Rally 35.36%: Here's is How to Trade (Zacks)
09:50AM	Why Perrigo (PRGO) is a Top Momentum Stock for the Long-Term (Zacks)
Jul-14-25 08:30AM	Perrigo Announces Agreement to Divest Dermacosmetics Business for up to 327 Million (PR Newswire)
Jul-09-25 09:40AM	Should Value Investors Buy Perrigo (PRGO) Stock? (Zacks)
Jul-02-25 09:15AM	Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jul-01-25 04:30PM	Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance (PR Newswire)
09:02AM	Good Start Dr. Brown's Launches 30-Day "Gentle Baby Formula Giveaway Contest" with a Generous Donation to Baby2Baby (PR Newswire)
Jun-23-25 09:40AM	Should Value Investors Buy Perrigo (PRGO) Stock? (Zacks)
Jun-20-25 09:48AM	These 3 Dividend Stocks Combine Strong Yields With Upside (MarketBeat)
Jun-11-25 09:55AM	Does Perrigo (PRGO) Have the Potential to Rally 32.86% as Wall Street Analysts Expect? (Zacks)
Jun-06-25 11:31AM	Why Is Perrigo (PRGO) Down 3.1% Since Last Earnings Report? (Zacks)
09:40AM	Are Investors Undervaluing Perrigo (PRGO) Right Now? (Zacks)
Jun-04-25 08:30AM	Perrigo Announces Global Operations and Supply Chain Leadership Transition (PR Newswire)
May-23-25 09:17AM	Perrigo to Attend the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference (PR Newswire)
May-22-25 09:55AM	Wall Street Analysts Predict a 27.28% Upside in Perrigo (PRGO): Here's What You Should Know (Zacks)
May-21-25 09:40AM	Is Perrigo (PRGO) Stock Undervalued Right Now? (Zacks)
09:10AM	How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks (Zacks)
May-14-25 10:55AM	Perrigo Company plc (PRGO): One of the Best Dividend Growth Stocks with High Yields (Insider Monkey)
May-13-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:16AM	Perrigo (PRGO) Reliance on International Sales: What Investors Need to Know (Zacks)
May-08-25 03:10AM	Perrigo Co PLC (PRGO) Q1 2025 Earnings Call Highlights: Strong Infant Formula Sales and Margin ... (GuruFocus.com)
May-07-25 06:43PM	Analyst Report: Perrigo Company plc (Morningstar Research) +7.01%
03:56PM	Is Perrigo Company plc (PRGO) the Best Mid-Cap Dividend Aristocrat to Invest in Now? (Insider Monkey)
02:14PM	Perrigo Company plc (PRGO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
09:30AM	Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
07:45AM	Perrigo (PRGO) Q1 Earnings Beat Estimates (Zacks)
06:41AM	Perrigo: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations (PR Newswire)
May-05-25 09:54AM	Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock? (Zacks)
May-01-25 10:01AM	Prestige Consumer Healthcare (PBH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-30-25 10:23AM	Perrigo Announces Quarterly Dividend (PR Newswire)
10:01AM	Perrigo (PRGO) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-24-25 06:21PM	Perrigo: Opill Shows Where The Company Wants To Be (Seeking Alpha)
Apr-23-25 04:47PM	Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025 (PR Newswire)
Apr-21-25 10:29AM	Is Perrigo Co. PLC (PRGO) an Economically Resilient Company? (Insider Monkey)
Apr-10-25 10:40PM	Heartland Mid Cap Value Fund Q1 2025 Commentary (Seeking Alpha) -5.84%
11:36AM	Sanara MedTech (SMTI) Stock Jumps 8.1%: Will It Continue to Soar? (Zacks)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha) +5.38%
Apr-02-25 06:20AM	Is ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) a Strong ETF Right Now? (Zacks)
Mar-22-25 12:31AM	Dividend Champion, Contender, And Challenger Highlights: Week Of March 23 (SeekingAlpha)
Mar-05-25 09:15AM	Investing in Perrigo (PRGO)? Don't Miss Assessing Its International Revenue Trends (Zacks)
Mar-04-25 01:41AM	Is Perrigo (PRGO) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)

Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lennox Abigail	EVP and CSO	Feb 06 '26	Option Exercise	14.64	3,185	46,628	4,440	Feb 10 04:33 PM
Parker Geoffrey M.	Director	Nov 12 '25	Buy	14.18	7,500	106,350	17,375	Nov 14 10:45 AM
Ball David	EVP & CBDO	Sep 09 '25	Option Exercise	22.28	7,701	171,578	7,701	Sep 11 05:00 PM
Lennox Abigail	EVP and CSO	Sep 08 '25	Buy	22.41	1,255	28,125	1,255	Sep 10 04:19 PM
Atkinson Charles	EVP, General Counsel & Sec.	Sep 05 '25	Buy	23.20	1,000	23,200	1,000	Sep 09 03:47 PM
Willis Robert	EVP & CHRO	Aug 22 '25	Buy	24.10	1,488	35,858	41,939	Aug 22 01:27 PM
Parker Geoffrey M.	Director	Aug 18 '25	Buy	22.97	4,375	100,497	33,287	Aug 19 10:56 AM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Aug 18 '25	Buy	22.74	3,000	68,207	48,949	Aug 19 10:41 AM
Lockwood-Taylor Patrick	CEO	Aug 08 '25	Buy	22.37	4,460	99,766	85,812	Aug 08 11:45 AM
Lockwood-Taylor Patrick	CEO	Jul 10 '25	Option Exercise	27.27	28,326	772,450	95,586	Jul 14 03:23 PM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Jun 06 '25	Option Exercise	26.16	4,531	118,531	47,732	Jun 10 11:22 AM
Khoury Roberto	EVP and President of CSCI	Jun 06 '25	Option Exercise	26.16	10,868	284,307	7,888	Jun 10 11:22 AM
Doyle Katherine C.	Former Director	Jun 05 '25	Proposed Sale	26.21	11,159	292,477		Jun 05 03:47 PM
Brown Julia M	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	12,788	May 16 11:53 AM
Alford Bradley A	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	45,914	May 16 11:53 AM
O'Connor Donal	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	35,391	May 16 11:52 AM
Parker Geoffrey M.	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	33,666	May 16 11:52 AM
KINDLER JEFFREY B	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	15,313	May 16 11:52 AM
Karaboutis Adriana	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	32,383	May 16 11:52 AM
Manzone Albert	Director	May 14 '25	Option Exercise	26.01	9,904	257,603	17,309	May 16 11:52 AM
ASHFORD ORLANDO D	Director	May 14 '25	Option Exercise	26.01	12,380	322,004	28,113	May 16 11:51 AM
Parker Geoffrey M.	Director	May 12 '25	Buy	27.10	3,500	94,850	23,762	May 14 02:06 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Apr 04 '25	Option Exercise	26.31	2,707	71,221	36,373	Apr 08 08:10 AM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Apr 04 '25	Option Exercise	26.31	6,370	167,595	45,655	Apr 08 08:10 AM
Schmelter Triona	EVP & President CSCA	Apr 04 '25	Option Exercise	26.31	5,733	150,835	8,310	Apr 08 08:10 AM
Lockwood-Taylor Patrick	CEO	Apr 04 '25	Option Exercise	26.31	17,835	469,239	73,708	Apr 08 08:10 AM
Willis Robert	EVP & CHRO	Apr 04 '25	Option Exercise	26.31	2,070	54,462	41,530	Apr 08 08:10 AM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 07 '25	Option Exercise	27.76	2,941	81,642	40,745	Mar 10 08:07 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 06 '25	Option Exercise	28.68	2,300	65,964	42,159	Mar 10 08:07 PM
Janish Ronald Craig	EVP, Gbl Ops & SC & CTO	Mar 10 '25	Sale	27.44	7,800	214,032	33,666	Mar 10 08:07 PM
Willis Robert	EVP & CHRO	Mar 07 '25	Option Exercise	27.76	2,163	60,045	39,745	Mar 10 08:07 PM
Willis Robert	EVP & CHRO	Mar 06 '25	Option Exercise	28.68	1,759	50,448	40,377	Mar 10 08:07 PM
Bezerra Eduardo Guarita	EVP & Chief Financial Officer	Mar 06 '25	Option Exercise	28.68	4,870	139,672	40,556	Mar 10 08:07 PM
Janish Ronald Craig	Officer	Mar 10 '25	Proposed Sale	27.44	7,800	214,032		Mar 10 02:45 PM
Brown Julia M	Director	Mar 05 '25	Option Exercise	29.47	5,548	163,500	5,548	Mar 07 10:21 AM
Andersen Svend	Officer	Mar 03 '25	Proposed Sale	29.53	27,000	797,369		Mar 03 03:51 PM
Andersen Svend	Former Officer	Mar 03 '25	Proposed Sale	30.30	17,343	525,416		Mar 03 10:48 AM

Open in Screener

PGEN

Precigen Inc

Feb 13 • 04:00PM ET

4.93

+0.19 4.01 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX REGN GILD ILMN INCY SRPT BLUE ARWR

| Held by: XBI IWM VTI VXF IWO IBB SCHA VTWO KOMP IWC

Index	RUT	P/E	-	EPS (ttm)	-1.40	Insider Own	57.09%	Shs Outstand	353.81M	Perf Week	14.92%
Market Cap	1.74B	Forward P/E	-	EPS next Y	-0.18	Insider Trans	-5.62%	Shs Float	151.81M	Perf Month	11.79%
Enterprise Value	1.72B	PEG	-	EPS next Q	-0.08	Inst Own	38.05%	Short Float	27.65%	Perf Quarter	22.64%
Income	-425.87M	P/S	276.44	EPS this Y	-86.70%	Inst Trans	12.48%	Short Ratio	9.49	Perf Half Y	166.49%
Sales	6.31M	P/B	41.66	EPS next Y	79.45%	ROA	-193.82%	Short Interest	41.98M	Perf YTD	17.94%
Book/sh	0.12	P/C	14.40	EPS next 5Y	-	ROE	-507.72%	52W High	5.22 -5.65%	Perf Year	148.99%
Cash/sh	0.34	P/FCF	-	EPS past 3/5Y	-0.39% 25.76%	ROIC	-306.52%	52W Low	1.11 344.14%	Perf 3Y	210.06%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.96% -46.64%	Gross Margin	10.14%	Volatility	8.32% 8.75%	Perf 5Y	-40.82%
Dividend TTM	-	EV/Sales	272.81	EPS Y/Y TTM	-155.65%	Oper. Margin	-1706.63%	ATR (14)	0.37	Perf 10Y	-83.22%
Dividend Ex-Date	-	Quick Ratio	3.95	Sales Y/Y TTM	59.20%	Profit Margin	-6750.13%	RSI (14)	58.69	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	4.04	EPS Q/Q	-1118.87%	SMA20	6.78%	Beta	1.06	Target Price	8.50
Payout	-	Debt/Eq	2.35	Sales Q/Q	206.61%	SMA50	14.63%	Rel Volume	0.54	Prev Close	4.74
Employees	143	LT Debt/Eq	2.32	Earnings	Nov 13 AMC	SMA200	57.94%	Avg Volume	4.42M	Price	4.93
IPO	Aug 08, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1028.86% 484.40%	Trades		Volume	2,404,572	Change	4.01%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Upgrade	JP Morgan	Underweight → Neutral
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight	$7
Feb-25-21	Initiated	Stifel	Buy	$13
Feb-22-21	Initiated	Wells Fargo	Overweight	$14
Feb-18-21	Initiated	B. Riley Securities	Buy	$10
May-08-20	Initiated	H.C. Wainwright	Buy	$5

Feb-13-26 07:14AM	Precigen, Inc. (PGEN) Builds Commercial Stage With Global Regulatory Support (Insider Monkey)
Jan-20-26 08:05AM	New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
Jan-12-26 08:00AM	Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) -9.91%
Jan-05-26 04:05PM	Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.85%
Nov-14-25 12:01AM	Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... (GuruFocus.com) +25.65%
04:05PM	Loading…
Nov-13-25 04:05PM	Precigen Reports Third Quarter 2025 Financial Results and Business Updates (PR Newswire)
Nov-06-25 04:30PM	Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 (PR Newswire)
Oct-26-25 06:05AM	Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS (Insider Monkey)
Oct-13-25 07:00AM	Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
Sep-23-25 07:23PM	Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization (Insider Monkey)
Sep-20-25 02:43AM	Precigen, Inc. (PGEN) Bolsters Financial Standing to Enhance PAPZIMEOS Commercialization (Insider Monkey)
Sep-15-25 08:17AM	Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS (Insider Monkey) -5.28%
Sep-12-25 03:41AM	4 years from clinic to approval Precigens unprecedented FDA nod and what comes next (Pharma Voice) -8.45%
Sep-11-25 03:31AM	Precigen's (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism (Insider Monkey)
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
07:00AM	Loading…
Sep-03-25 07:00AM	Precigen Announces Up to $125 Million Non-Dilutive Financing (PR Newswire)
Sep-02-25 12:57AM	Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN) (Insider Monkey) +5.54%
Aug-28-25 10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 08:39AM	Citizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform Rating (Insider Monkey) +7.04%
Aug-25-25 11:56PM	H.C. Wainwright Remains Bullish on Precigen (PGEN) (Insider Monkey)
11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:05AM	Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright (PR Newswire)
Aug-20-25 12:22AM	Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:42AM	FDA approves Papzimeos as first therapy for HPV-caused airway disease (Pharmaceutical Technology)
Aug-15-25 10:45AM	Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis (RRP) (Business Wire) +58.92%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:20AM	Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial (BioPharma Dive)
07:00AM	Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
04:05PM	Loading…
May-14-25 04:05PM	Precigen Reports First Quarter 2025 Financial Results and Business Updates (PR Newswire) -5.19%
Apr-22-25 12:00PM	Patient Capital Management Q1 2025 Investment Review (Seeking Alpha) +11.68%
Apr-16-25 08:05AM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-25 10:19AM	Is Precigen (PGEN) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-21-25 06:23PM	Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Mar-19-25 07:47PM	Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript (SeekingAlpha) +7.19%
06:25PM	Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Precigen Reports Full Year 2024 Financial Results and Business Updates (PR Newswire)
Mar-13-25 08:05AM	Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th (PR Newswire)
Mar-01-25 05:27PM	Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-25-25 08:05AM	FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 (PR Newswire)
Jan-13-25 07:00AM	Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire) -8.94%
Jan-09-25 08:30AM	Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-30-24 07:00AM	Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire) +28.47%
Dec-27-24 09:00AM	Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock (PR Newswire)
Nov-14-24 04:30PM	Precigen Reports Third Quarter 2024 Financial Results and Business Updates (PR Newswire) -7.11%
Nov-12-24 04:05PM	Precigen to Participate in the Stifel 2024 Healthcare Conference (PR Newswire) -5.04%
Sep-16-24 04:30PM	Precigen to Participate in the 2024 Cantor Global Healthcare Conference (PR Newswire)
Aug-14-24 04:05PM	Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates (PR Newswire)
01:54PM	Hedge Fund and Insider Trading News: Nelson Peltz, Jana Partners, Whitebox Advisors, Caxton Associates LP, Altium Capital, Soros Fund Management, Elliott Investment Management, Balyasny Asset Management, Precigen Inc (PGEN), Vulcan Materials Company (VMC), and More (Insider Monkey)
Aug-09-24 08:00AM	Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th (PR Newswire) -13.39%
Aug-07-24 09:30PM	Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock (PR Newswire) -12.59% +7.63%
Aug-06-24 04:04PM	Precigen Announces Proposed $30 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch (PR Newswire)
Jul-23-24 08:01AM	Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch (PR Newswire)
Jun-03-24 09:30AM	Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response (PR Newswire) +11.43%
May-23-24 05:00PM	Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 05:20PM	Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.11%
04:05PM	Precigen Reports First Quarter 2024 Financial Results and Business Updates (PR Newswire)
08:21AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:05PM	Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting (PR Newswire)
Apr-24-24 10:20AM	Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting (PR Newswire)
09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Mar-28-24 04:05PM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-24 08:20AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-20-24 10:07AM	Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:31PM	Precigen Inc (PGEN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Precigen Reports Full Year 2023 Financial Results and Business Updates (PR Newswire)
Mar-12-24 04:05PM	Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Mar-05-24 04:05PM	Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th (PR Newswire)
Feb-06-24 04:05PM	Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-16-24 08:05AM	Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission (PR Newswire)
Jan-08-24 08:30AM	Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.53%
Jan-02-24 12:40PM	Hedge Fund and Insider Trading News: David Einhorn, Bill Ackman, D. E. Shaw, Steve Cohen, Rob Citrone, Saba Capital, HighPeak Energy, Inc (HPK), Precigen Inc (PGEN), and More (Insider Monkey) +5.22%
Dec-18-23 04:05PM	Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.74%
Nov-29-23 04:05PM	Precigen to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-09-23 04:55PM	Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs (PR Newswire) -13.49%
Nov-07-23 04:05PM	Precigen to Participate in the Stifel 2023 Healthcare Conference (PR Newswire) +12.93%
Sep-19-23 04:05PM	Precigen to Participate in Upcoming Leading Investor and Industry Conferences (PR Newswire) -8.33% +6.06%
Aug-09-23 08:00AM	Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 (PR Newswire) +6.90%
07:05AM	Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval (PR Newswire)
Aug-03-23 04:05PM	Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th (PR Newswire) -6.67%
Jun-20-23 07:30AM	Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Jun-05-23 04:05PM	Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients (PR Newswire)
Jun-03-23 12:00PM	Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers (PR Newswire)
May-31-23 08:05AM	Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer (PR Newswire)
May-10-23 08:00AM	Precigen Reports First Quarter 2023 Financial Results and Business Updates (PR Newswire)
May-03-23 08:30AM	Precigen to Announce First Quarter 2023 Financial Results on May 10th (PR Newswire) +8.85%
Apr-26-23 04:05PM	Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy at the 2023 ASCO Annual Meeting (PR Newswire)
Apr-17-23 09:01AM	Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023 (PR Newswire) +10.48%
Apr-03-23 04:30PM	Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® (PR Newswire) +5.66% -8.04%
Mar-29-23 08:05AM	Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors (PR Newswire) +15.44%
Mar-28-23 08:05AM	Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium (PR Newswire)
Mar-06-23 04:05PM	Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (PR Newswire) +17.39%
Feb-07-23 08:00AM	Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response (News Direct)
Jan-30-23 02:34PM	Germantown's Precigen raises $75M to advance treatments for rare diseases (American City Business Journals)
Jan-27-23 04:05PM	Precigen Announces Closing of Public Offering of Common Stock (PR Newswire)
Jan-24-23 10:40PM	Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock (PR Newswire) -24.66%
04:05PM	Precigen Announces Proposed $75.0 Million Public Offering of Common Stock (PR Newswire)

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIRK RANDAL J	Director	Dec 22 '25	Sale	4.18	1,900,036	7,942,150	341,189	Dec 22 08:48 PM
Randal J. Kirk	Director	Dec 22 '25	Proposed Sale	4.32	1,900,036	8,208,156		Dec 22 08:19 PM
KINDLER JEFFREY B	Director	Dec 12 '25	Sale	3.63	235,467	855,899	110,603	Dec 16 04:16 PM
Jeffrey Kindler	Director	Dec 12 '25	Proposed Sale	3.69	235,467	868,873		Dec 12 06:27 PM
KIRK RANDAL J	Director	Nov 19 '25	Sale	4.47	1,086,153	4,855,104	7,434,384	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 20 '25	Sale	4.08	942,832	3,846,755	6,491,552	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 21 '25	Sale	3.83	937,308	3,589,890	5,554,244	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 20 '25	Proposed Sale	4.08	942,832	3,843,885		Nov 20 05:33 PM
KIRK RANDAL J	Director	Nov 19 '25	Proposed Sale	4.22	1,086,153	4,583,565		Nov 19 05:23 PM
KINDLER JEFFREY B	Director	Sep 30 '25	Sale	3.38	106,837	361,109	346,070	Oct 01 05:16 PM
KINDLER JEFFREY B	Director	Sep 29 '25	Sale	3.60	67,523	243,083	452,907	Oct 01 05:16 PM
KIRK RANDAL J	Director	Sep 30 '25	Sale	3.41	1,809,667	6,170,964	14,597,161	Sep 30 05:44 PM
KIRK RANDAL J	Director	Sep 30 '25	Proposed Sale	3.63	1,809,667	6,569,091		Sep 30 05:26 PM
Jeffrey Kindler	Director	Sep 30 '25	Proposed Sale	3.29	106,837	351,494		Sep 30 04:21 PM
Shah Rutul R	Chief Operating Officer	Sep 26 '25	Buy	3.40	2,000	6,800	405,959	Sep 30 04:07 PM
Tennant Phil	Chief Commercial Officer	Sep 29 '25	Buy	3.58	6,000	21,480	65,031	Sep 30 04:04 PM
Jeffrey Kindler	Director	Sep 29 '25	Proposed Sale	3.63	67,523	245,108		Sep 29 04:12 PM
Thomasian Harry Jr.	Chief Financial Officer	Sep 25 '25	Buy	3.62	8,284	29,988	465,694	Sep 26 05:01 PM
Thomasian Harry Jr.	Chief Financial Officer	Sep 26 '25	Buy	3.42	2,932	10,027	468,626	Sep 26 05:01 PM
KIRK RANDAL J	Director	Sep 19 '25	Sale	3.68	3,596,892	13,236,563	8,520,537	Sep 19 08:46 PM
KIRK RANDAL J	Director	Sep 18 '25	Sale	3.86	1,403,360	5,416,970	12,117,429	Sep 19 08:46 PM
KIRK RANDAL J	Director	Sep 19 '25	Proposed Sale	3.85	252	970		Sep 19 04:47 PM
KIRK RANDAL J	Director	Sep 18 '25	Proposed Sale	3.92	5,000,000	19,625,000		Sep 18 01:30 PM
AGEE NANCY H	Director	Sep 04 '25	Buy	4.60	15,000	69,000	217,841	Sep 05 05:46 PM
AGEE NANCY H	Director	Aug 28 '25	Buy	4.65	10,645	49,491	202,841	Aug 29 04:21 PM
AGEE NANCY H	Director	Aug 19 '25	Buy	3.20	15,360	49,152	192,196	Aug 29 04:21 PM
KIRK RANDAL J	Director	Mar 14 '25	Option Exercise	0.00	174,825	0	64,779,510	Mar 17 06:38 PM

PRGO

Perrigo Company plc

PGEN

Precigen Inc

Upgrade your FINVIZ experience